Galapagos NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Galapagos NV Discovers Novel Candidate Drug To Treat Breast Cancer
Galapagos NV announced that it developed GLPG1790, a candidate drug to treat breast cancer. GLPG1790 has shown activity against breast tumors that are triple-negative, for which the absence of estrogen (ER), progesterone (PR) or HER2 receptors affects the prognosis for recovery, and no targeted therapeutic options are currently available. Candidate drug GLPG1790 is a selective and potent inhibitor of a breast cancer target; the candidate drug has proven to be active against triple-negative breast cancer in a mouse xenograft model where it completely blocks tumor growth. GLPG1790 has drug-like properties, and safety/tolerability studies with the candidate drug look favorable. Galapagos will initiate preclinical studies with GLPG1790, and expects to initiate the first clinical trials in humans within one year. This program is fully proprietary to the Company.
Latest Developments for Galapagos NV
Latest Key Developments in Biotechnology
- Share this
- Digg this